NYSE:CHE - Chemed Stock Price, Price Target & More

$302.70 -0.15 (-0.05 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$302.85

Today's Range$300.18 - $305.26

52-Week Range$184.61 - $313.25

Volume131,894 shs

Average Volume109,195 shs

Market Capitalization$4.89 billion

P/E Ratio56.54

Dividend Yield0.38%

Beta1.05

About Chemed (NYSE:CHE)

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and operated territories, independent contractor-operated territories, and franchised locations. This segment also manufactures and sells products and equipment, including drain cleaning machines and drain cleaning solutions. The company was founded in 1970 and is headquartered in Cincinnati, Ohio.

Receive CHE News and Ratings via Email

Sign-up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services

Sub-IndustryHealth Care Services

SectorMedical

SymbolNYSE:CHE

CUSIP16359R10

Webwww.chemed.com

Phone513-762-6690

Debt

Debt-to-Equity Ratio0.26%

Current Ratio0.91%

Quick Ratio0.88%

Price-To-Earnings

Trailing P/E Ratio56.54

Forward P/E Ratio28.24

P/E Growth2.83

Sales & Book Value

Annual Sales$1.67 billion

Price / Sales2.93

Cash Flow$7.9658 per share

Price / Cash38.00

Book Value$33.84 per share

Price / Book8.95

Profitability

EPS (Most Recent Fiscal Year)$5.36

Net Income$98.17 million

Net Margins6.67%

Return on Equity33.05%

Return on Assets17.97%

Miscellaneous

Employees14,813

Outstanding Shares16,160,000

How to Become a New Pot Stock Millionaire

Chemed (NYSE:CHE) Frequently Asked Questions

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed announced a quarterly dividend on Friday, February 16th. Shareholders of record on Monday, February 26th will be paid a dividend of $0.28 per share on Monday, March 19th. This represents a $1.12 dividend on an annualized basis and a yield of 0.37%. The ex-dividend date is Friday, February 23rd. View Chemed's Dividend History.

How will Chemed's stock buyback program work?

Chemed declared that its board has approved a share repurchase plan on Wednesday, March 7th 2018, which authorizes the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

How were Chemed's earnings last quarter?

Chemed Corp. (NYSE:CHE) posted its quarterly earnings results on Thursday, April, 19th. The company reported $2.72 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.36 by $0.36. The business had revenue of $439.18 million for the quarter, compared to analysts' expectations of $419.33 million. Chemed had a return on equity of 33.05% and a net margin of 6.67%. The business's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 earnings per share. View Chemed's Earnings History.

When is Chemed's next earnings date?

Chemed is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Chemed.

What guidance has Chemed issued on next quarter's earnings?

Chemed updated its FY18 earnings guidance on Thursday, April, 19th. The company provided earnings per share guidance of $10.60-10.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.72.

What price target have analysts set for CHE?

3 brokers have issued 1 year price targets for Chemed's shares. Their predictions range from $258.00 to $275.00. On average, they anticipate Chemed's stock price to reach $266.50 in the next twelve months. View Analyst Ratings for Chemed.

Who are some of Chemed's key competitors?

Some companies that are related to Chemed include Alnylam Pharmaceuticals (ALNY), Eurofins Scientific (ERFSF), Jazz Pharmaceuticals (JAZZ), BioMérieux (BMXMF), BeiGene (BGNE), WellCare (WCG), bluebird bio (BLUE), STERIS (STE), Seattle Genetics (SGEN), Bio-Rad Laboratories (BIO), Valeant Pharmaceuticals International (VRX), AveXis (AVXS), Neurocrine Biosciences (NBIX), Alkermes (ALKS), SAGE Therapeutics (SAGE), West Pharmaceutical Services (WST), Stada Arzneimittel (STDAF) and ICON (ICLR).

Who are Chemed's key executives?

Chemed's management team includes the folowing people:

Mr. Kevin J. McNamara, Pres, CEO & Director (Age 64)
Mr. David P. Williams, Exec. VP & CFO (Age 57)
Mr. Spencer S. Lee, Exec. VP (Age 62)
Mr. Nicholas Michael Westfall, Exec. VP (Age 39)
Mr. Timothy S. O'Toole, Consultant (Age 62)

Has Chemed been receiving favorable news coverage?

News headlines about CHE stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemed earned a media sentiment score of 0.08 on Accern's scale. They also gave news coverage about the company an impact score of 46.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Chemed's major shareholders?

Chemed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include GAMCO INVESTORS, INC. ET AL (4.28%). Company insiders that own Chemed stock include Arthur V Tucker Jr, David Patrick Williams, Donald E Saunders, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace and Spencer S Lee. View Institutional Ownership Trends for Chemed.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $302.70.

How big of a company is Chemed?

Chemed has a market capitalization of $4.89 billion and generates $1.67 billion in revenue each year. The company earns $98.17 million in net income (profit) each year or $5.36 on an earnings per share basis. Chemed employs 14,813 workers across the globe.

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.

MarketBeat Community Rating for Chemed (CHE)

Community Ranking:		2.0 out of 5 ( )
Outperform Votes:		146 (Vote Outperform)
Underperform Votes:		214 (Vote Underperform)
Total Votes:		360

MarketBeat's community ratings are surveys of what our community members think about Chemed and other stocks. Vote "Outperform" if you believe CHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Chemed (NYSE:CHE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Chemed in the last 12 months. Their average twelve-month price target is $266.50, suggesting that the stock has a possible downside of 11.96%. The high price target for CHE is $275.00 and the low price target for CHE is $258.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.33	2.33	2.33	2.50
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$266.50	$266.50	$228.50	$214.50
Price Target Upside:	11.96% downside	4.40% upside	2.63% upside	5.41% upside

Chemed (NYSE:CHE) Consensus Price Target History

Price Target History for Chemed (NYSE:CHE)

Chemed (NYSE:CHE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/16/2018	Oppenheimer	Boost Price Target	Outperform	$270.00 -> $275.00	Low
2/16/2018	Royal Bank of Canada	Reiterated Rating	Hold	$258.00	Low
10/27/2017	KeyCorp	Reiterated Rating	Hold		N/A
8/13/2017	National Bank Financial	Upgrade	Sector Perform Market Weight -> Outperform Market Weight		N/A
9/4/2016	JMP Securities	Reiterated Rating	Hold		N/A

(Data available from 4/23/2016 forward)

Chemed (NYSE:CHE) Earnings History and Estimates Chart

Earnings by Quarter for Chemed (NYSE:CHE)

Chemed (NYSE:CHE) Earnings Estimates

2018 EPS Consensus Estimate: $8.61

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$1.95	$1.95	$1.95
Q2 2018	1	$2.09	$2.09	$2.09
Q3 2018	1	$2.14	$2.14	$2.14
Q4 2018	1	$2.43	$2.43	$2.43

Chemed (NYSE CHE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/24/2018
4/19/2018	Q1 2018	$2.36	$2.72	$419.33 million	$439.18 million	View	N/A
2/14/2018	Q4 2017	$2.27	$2.32	$423.83 million	$428.35 million	View	Listen
10/26/2017	Q3 2017	$2.00	$2.15	$414.34 million	$417.40 million	View	N/A
7/25/2017	Q2 2017	$1.89	$2.15	$407.56 million	$415.06 million	View	N/A
4/26/2017	Q1 2017	$1.78	$1.82	$399.75 million	$405.90 million	View	N/A
2/15/2017	Q416	$2.10	$2.10	$409.89 million	$403.00 million	View	Listen
10/26/2016	Q316	$1.82	$1.73	$270.44 million	$392.61 million	View	Listen
7/25/2016	Q216	$1.72	$1.80	$393.50 million	$290.00 million	View	Listen
4/28/2016	Q116	$1.58	$1.62	$391.68 million	$390.40 million	View	Listen
2/17/2016	Q415	$1.81	$1.97	$390.22 million	$398.60 million	View	Listen
10/22/2015	Q315	$1.61	$1.78	$375.95 million	$386.23 million	View	Listen
7/23/2015	Q215	$1.59	$1.71	$375.01 million	$382.00 million	View	Listen
4/28/2015	Q115	$1.35	$1.54	$370.76 million	$377.00 million	View	Listen
2/17/2015	Q414	$1.65	$1.80	$372.54 million	$379.00 million	View	Listen
10/30/2014	Q314	$1.34	$1.40	$360.00 million	$358.40 million	View	Listen
8/7/2014		$0.32	$0.30	$319.70 million	$310.06 million	View	N/A
7/23/2014	Q214	$1.31	$1.50	$363.73 million	$360.18 million	View	Listen
4/29/2014	Q114	$1.23	$1.32	$256.77 million	$358.30 million	View	Listen
2/17/2014	Q4 2013		$1.40	$356.02 million	$348.60 million	View	N/A
10/29/2013	Q313	$1.34	$1.36	$355.40 million	$340.90 million	View	Listen
7/18/2013	Q2 2013	$1.33	$1.44	$368.06 million	$357.00 million	View	Listen
4/18/2013	Q1 2013	$1.29	$1.38	$365.08 million	$367.00 million	View	Listen
2/18/2013	Q4 2012	$1.15	$1.57	$355.31 million	$369.00 million	View	Listen
10/29/2012	Q312	$1.35	$1.28	$360.50 million	$354.00 million	View	N/A
7/25/2012		$1.26	$1.26			View	N/A
4/19/2012		$1.25	$1.21			View	N/A
2/14/2012		$1.48	$1.45			View	N/A
10/25/2011		$1.15	$1.20			View	N/A
7/26/2011	Q2 2011	$1.07	$1.01			View	N/A
4/26/2011		$0.98	$1.07			View	N/A
2/15/2011		$1.05	$0.98			View	N/A
10/25/2010	Q3 2010	$0.93	$0.97			View	N/A
7/28/2010	Q2 2010	$0.91	$0.92			View	N/A
4/20/2010	Q1 2010	$0.91	$0.89			View	N/A
2/15/2010	Q4 2009	$0.94	$1.00			View	N/A
10/27/2009	Q3 2009	$0.89	$0.90			View	N/A
7/30/2009	Q2 2009	$0.83	$0.90			View	N/A
4/22/2009	Q1 2009	$0.84	$0.94			View	N/A
2/16/2009	Q4 2008	$0.92	$0.93			View	N/A
10/21/2008	Q3 2008	$0.76	$0.79			View	N/A
7/28/2008	Q2 2008	$0.72	$0.73			View	N/A
4/24/2008	Q1 2008	$0.85	$0.69			View	N/A
2/21/2008	Q4 2007	$0.87	$0.92			View	N/A

(Earnings results data provided by Zacks Investment Research)

Chemed (NYSE:CHE) Dividend Information

Chemed pays an annual dividend of $1.12 per share, with a dividend yield of 0.37%. CHE's most recent quarterly dividend payment was Monday, March 19. The company has grown its dividend for the last 9 consecutive years and is increasing its dividend by an average of 8.70% each year. Chemed pays out 20.90% of its earnings out as a dividend.

Most Recent Dividend:	3/19/2018
Annual Dividend:	$1.12
Dividend Yield:	0.37%
Dividend Growth:	8.70% (3 Year Average)
Payout Ratio:	20.90% (Trailing 12 Months of Earnings) 10.45% (Based on This Year's Estimates) 9.85% (Based on Next Year's Estimates)
Track Record:	9 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Chemed (NYSE:CHE)

Chemed (NYSE:CHE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/16/2018	quarterly	$0.28	0.41%	2/23/2018	2/26/2018	3/19/2018
11/3/2017	Quarterly	$0.28	0.48%	11/10/2017	11/13/2017	12/4/2017
9/22/2017	Monthly	$0.10		9/28/2017	9/29/2017	10/31/2017
8/23/2017	Monthly	$0.10		8/29/2017	8/31/2017	9/29/2017
8/4/2017	quarterly	$0.28	0.57%	8/10/2017	8/14/2017	9/1/2017
7/21/2017	Monthly	$0.10		7/27/2017	7/31/2017	8/31/2017
6/22/2017	Monthly	$0.10		6/28/2017	6/30/2017	7/31/2017
5/15/2017	Quarterly	$0.26	0.51%	5/23/2017	5/25/2017	6/14/2017
2/17/2017	quarterly	$0.26	0.59%	2/23/2017	2/27/2017	3/20/2017
11/4/2016	quarterly	$0.26	0.76%	11/9/2016	11/14/2016	12/5/2016
8/5/2016	quarterly	$0.26	0.72%	8/11/2016	8/15/2016	9/2/2016
5/16/2016	quarterly	$0.24	0.76%	5/24/2016	5/26/2016	6/15/2016
2/19/2016	quarterly	$0.24	0.75%	2/25/2016	2/29/2016	3/21/2016
11/6/2015	quarterly	$0.24	0.63%	11/12/2015	11/16/2015	12/7/2015
8/7/2015	quarterly	$0.24	0.63%	8/13/2015	8/17/2015	9/4/2015
5/18/2015	quarterly	$0.22	0.71%	5/26/2015	5/28/2015	6/17/2015
2/20/2015	quarterly	$0.22	0.77%	2/26/2015	3/2/2015	3/23/2015
11/7/2014	quarterly	$0.22	0.81%	11/13/2014	11/17/2014	12/8/2014
8/11/2014	quarterly	$0.22	0.88%	8/14/2014	8/18/2014	9/13/2014
8/8/2014	quarterly	$0.22		8/14/2014	8/18/2014	9/3/2014
5/19/2014	quarterly	$0.20	0.91%	5/27/2014	5/29/2014	6/18/2014
2/21/2014	quarterly	$0.20	0.94%	2/27/2014	3/3/2014	3/24/2014
11/8/2013	quarterly	$0.20	1.13%	11/14/2013	11/18/2013	12/9/2013
8/2/2013	quarterly	$0.20	1.1%	8/8/2013	8/12/2013	9/3/2013
5/20/2013	quarterly	$0.18	1.05%	5/28/2013	5/30/2013	6/19/2013
2/20/2013	quarterly	$0.18	0.92%	2/28/2013	3/4/2013	3/22/2013

(Data available from 1/1/2013 forward)

Chemed (NYSE CHE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.82%
Institutional Ownership Percentage: 94.77%

Insider Trading History for Chemed (NYSE:CHE)

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Chemed (NYSE CHE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Kevin J Mcnamara	Insider	Sell	6,000	$258.00	$1,548,000.00	140,049
2/21/2018	Naomi C Dallob	VP	Sell	1,050	$257.00	$269,850.00	6,649
12/4/2017	Michael D Witzeman	VP	Sell	1,000	$250.00	$250,000.00	3,334
11/29/2017	David Patrick Williams	Insider	Sell	11,000	$241.28	$2,654,080.00	74,857
11/27/2017	Naomi C Dallob	VP	Sell	950	$240.38	$228,361.00	9,747
11/22/2017	Spencer S Lee	Insider	Sell	1,000	$238.24	$238,240.00	34,809
11/16/2017	Michael D Witzeman	VP	Sell	1,579	$235.00	$371,065.00	4,334
11/15/2017	Kevin J Mcnamara	CEO	Sell	5,000	$232.59	$1,162,950.00	136,800
11/15/2017	Spencer S Lee	Insider	Sell	1,000	$232.27	$232,270.00	35,809
11/13/2017	Nicholas Michael Westfall	Insider	Sell	10,000	$231.00	$2,310,000.00	13,351
11/8/2017	Naomi C Dallob	VP	Sell	1,900	$231.00	$438,900.00	10,426
11/2/2017	Donald E Saunders	Director	Sell	500	$227.75	$113,875.00	10,298
11/2/2017	Spencer S Lee	EVP	Sell	1,000	$228.45	$228,450.00	36,809
10/31/2017	Kevin J Mcnamara	CEO	Sell	10,000	$223.42	$2,234,200.00	170,016
10/31/2017	Naomi C Dallob	VP	Sell	750	$222.09	$166,567.50	9,097
10/2/2017	Patrick P Grace	Director	Sell	500	$201.48	$100,740.00	4,515
9/1/2017	Spencer S Lee	Insider	Sell	1,000	$197.46	$197,460.00	37,809
7/28/2017	Kevin J Mcnamara	Insider	Sell	15,000	$201.16	$3,017,400.00	173,801
6/26/2017	George J Walsh III	Director	Buy	1,000	$204.56	$204,560.00	7,908
5/4/2017	Donald E Saunders	Director	Buy	94	$205.59	$19,325.46	9,886
5/3/2017	Donald E Saunders	Director	Sell	400	$204.85	$81,940.00	9,886
5/2/2017	Kevin J Mcnamara	Insider	Sell	4,000	$205.11	$820,440.00	148,943
5/1/2017	Spencer S Lee	Insider	Sell	1,000	$202.47	$202,470.00	39,147
3/3/2017	Kevin J Mcnamara	Insider	Sell	7,000	$181.74	$1,272,180.00	149,191
3/2/2017	Arthur V Tucker Jr	VP	Sell	2,266	$181.00	$410,146.00	1,800
2/27/2017	Arthur V Tucker Jr	VP	Sell	8,878	$179.21	$1,591,026.38	8,070
2/24/2017	Kevin J Mcnamara	Insider	Sell	7,000	$177.63	$1,243,410.00	160,010
11/28/2016	Patrick P Grace	Director	Sell	400	$148.53	$59,412.00	4,597
11/14/2016	Donald E Saunders	Director	Sell	500	$149.56	$74,780.00	10,286
11/14/2016	Spencer S Lee	Insider	Sell	4,500	$150.22	$675,990.00	35,367
10/31/2016	Kevin J Mcnamara	Insider	Sell	10,000	$138.40	$1,384,000.00	189,266
9/22/2016	Spencer S Lee	Insider	Sell	2,000	$141.67	$283,340.00	39,867
8/8/2016	Donald E Saunders	Director	Sell	500	$144.32	$72,160.00	10,786
8/5/2016	Arthur V Tucker Jr	VP	Sell	4,500	$144.28	$649,260.00	7,734
8/4/2016	Arthur V Tucker Jr	VP	Sell	3,089	$143.88	$444,445.32	3,234
8/3/2016	Kevin J Mcnamara	Insider	Sell	18,000	$144.87	$2,607,660.00	163,266
5/16/2016	Donald E Saunders	Director	Buy	77	$126.53	$9,742.81	11,209
3/21/2016	Spencer S Lee	EVP	Sell	24,382	$132.29	$3,225,494.78	62,087
1/27/2016	Patrick P Grace	Director	Sell	50	$138.98	$6,949.00	4,522
12/11/2015	David Patrick Williams	CFO	Sell	5,000	$151.72	$758,600.00	36,968
11/24/2015	Spencer S Lee	EVP	Sell	5,000	$154.10	$770,500.00	43,405
11/6/2015	Kevin J Mcnamara	CEO	Sell	6,000	$157.02	$942,120.00	167,736
10/27/2015	Spencer S. Lee	EVP	Sell	4,000	$153.64	$614,560.00	48,405
10/26/2015	Kevin J. Mcnamara	CEO	Sell	8,000	$149.04	$1,192,320.00	173,736
8/24/2015	David Patrick Williams	CFO	Sell	10,000	$138.09	$1,380,900.00	29,268
5/15/2015	Arthur V Tucker Jr	VP	Sell	9,000	$121.00	$1,089,000.00
5/7/2015	Kevin J Mcnamara	CEO	Sell	8,000	$120.82	$966,560.00
3/6/2015	Spencer S Lee	EVP	Sell	9,931	$115.16	$1,143,653.96
3/2/2015	Timothy S Otoole	EVP	Sell	10,000	$117.82	$1,178,200.00
2/27/2015	Arthur V Tucker Jr	VP	Sell	7,000	$116.80	$817,600.00
2/24/2015	Arthur V Tucker Jr	VP	Sell	2,685	$114.35	$307,029.75
2/23/2015	Spencer S Lee	EVP	Sell	10,000	$113.18	$1,131,800.00
2/20/2015	Kevin J Mcnamara	CEO	Sell	13,000	$112.71	$1,465,230.00
11/14/2014	Timothy S Otoole	EVP	Sell	5,000	$106.81	$534,050.00
11/13/2014	Spencer S Lee	EVP	Sell	10,000	$108.38	$1,083,800.00
11/4/2014	Kevin J Mcnamara	CEO	Sell	4,000	$104.13	$416,520.00
9/10/2014	Spencer S Lee	EVP	Sell	2,000	$105.80	$211,600.00
9/8/2014	David Patrick Williams	CFO	Sell	5,000	$105.90	$529,500.00
8/7/2014	Kevin J Mcnamara	CEO	Sell	5,000	$100.05	$500,250.00
7/25/2014	Arthur V Tucker Jr	VP	Sell	9,000	$101.26	$911,340.00
7/25/2014	Kevin J Mcnamara	CEO	Sell	10,000	$101.00	$1,010,000.00
5/15/2014	Timothy Otoole	EVP	Sell	9,000	$87.62	$788,580.00	31,170
5/5/2014	Kevin Mcnamara	CEO	Sell	5,000	$85.05	$425,250.00	178,710
4/2/2014	Spencer Lee	EVP	Sell	2,000	$90.15	$180,300.00	65,848
3/19/2014	Thomas Hutton	VP	Sell	2,201	$88.36	$194,480.36	28,699
3/11/2014	Timothy Otoole	EVP	Sell	6,000	$86.60	$519,600.00	37,519
3/3/2014	Kevin Mcnamara	CEO	Sell	4,000	$84.47	$337,880.00	178,616
2/28/2014	Arthur Tucker, Jr.	VP	Sell	9,000	$85.01	$765,090.00	8,282
2/25/2014	Arthur Tucker, Jr.	VP	Sell	8,461	$83.80	$709,031.80	8,282
2/20/2014	Spencer Lee	EVP	Sell	2,000	$82.51	$165,020.00	67,848
2/19/2014	Kevin Mcnamara	CEO	Sell	4,000	$82.18	$328,720.00	182,616

(Data available from 1/1/2013 forward)

Chemed (NYSE CHE) News Headlines

Source:

Date	Headline
	Chemed's (CHE) CEO Kevin McNamara on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 20 at 5:01 PM
	Chemed Corporation (CHE) Tops Q1 EPS by 36c, Maintains Guidance www.streetinsider.com - April 20 at 8:53 AM
	Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View www.msn.com - April 20 at 8:53 AM
	Chemed (CHE) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS www.americanbankingnews.com - April 19 at 6:56 PM
	Chemed beats by $0.36, beats on revenue seekingalpha.com - April 19 at 5:14 PM
	Chemed Q1 top line up 8%; earnings up 51% seekingalpha.com - April 19 at 5:14 PM
	BRIEF-Chemed Corp Q1 GAAP Earnings Per Share $2.66 www.reuters.com - April 19 at 5:14 PM
	Chemed: 1Q Earnings Snapshot finance.yahoo.com - April 19 at 5:14 PM
	Chemed Reports First-Quarter 2018 Results finance.yahoo.com - April 19 at 5:14 PM
	Chemed (CHE) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 19 at 5:08 PM
	VITAS HEALTHCARE BRINGS EXPERTISE IN RISK MITIGATION AND VALUE-BASED CARE TO APG CONFERENCE IN SAN DIEGO finance.yahoo.com - April 18 at 4:57 PM
	Chemed (CHE) Cut to "Hold" at BidaskClub www.americanbankingnews.com - April 14 at 8:30 AM
	Chemed (CHE) Set to Announce Earnings on Thursday www.americanbankingnews.com - April 12 at 1:25 AM
	Form DEF 14A CHEMED CORP For: May 21 www.streetinsider.com - April 11 at 4:57 PM
	VITAS HEALTHCARE REFERRALS MADE EASIER WITH HOSPICE APP’S FACE SHEET finance.yahoo.com - April 9 at 5:05 PM
	Chemed (CHE) Stock Rating Reaffirmed by Royal Bank of Canada www.americanbankingnews.com - April 8 at 11:01 AM
	Chemed (CHE) Upgraded by ValuEngine to "Buy" www.americanbankingnews.com - April 3 at 5:52 PM
	Chemed (CHE) Rating Increased to A- at TheStreet www.americanbankingnews.com - April 2 at 9:42 PM
	Royal Bank of Canada Boosts Chemed (CHE) Price Target to $232.00 www.americanbankingnews.com - April 2 at 8:04 PM
	Chemed Co. (CHE) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 2 at 1:46 AM
	LHC Group (LHCG) & Chemed (CHE) Critical Review www.americanbankingnews.com - April 1 at 1:36 AM
	Critical Comparison: Chemed (CHE) versus BioTelemetry (BEAT) www.americanbankingnews.com - March 18 at 1:04 AM
	Chemed Corporation to Present at the Oppenheimer 28th Annual Healthcare Conference finance.yahoo.com - March 14 at 4:58 PM
	Chemed Co. (CHE) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - March 8 at 1:24 AM
	Chemed (CHE) Declares Share Buyback Plan www.americanbankingnews.com - March 7 at 11:49 AM
	Chemed Corporation’s Board of Directors Authorizes an Additional $150 Million for Stock Repurchase finance.yahoo.com - March 6 at 4:54 PM
	Chemed Co. (CHE) Stake Decreased by Formidable Asset Management LLC www.americanbankingnews.com - March 6 at 9:50 AM
	Chemed Co. (CHE) Shares Sold by Schroder Investment Management Group www.americanbankingnews.com - March 6 at 9:48 AM
	26,005 Shares in Chemed Co. (CHE) Purchased by WINTON GROUP Ltd www.americanbankingnews.com - March 5 at 4:09 PM
	State of Tennessee Treasury Department Decreases Position in Chemed Co. (CHE) www.americanbankingnews.com - March 5 at 3:28 PM
	Chemed Co. (CHE) Insider Sells $1,548,000.00 in Stock www.americanbankingnews.com - March 2 at 3:54 PM
	Investec Asset Management LTD Sells 27,574 Shares of Chemed Co. (CHE) www.americanbankingnews.com - March 2 at 3:47 PM
	Chemed Co. (CHE) Holdings Trimmed by Royce & Associates LP www.americanbankingnews.com - March 2 at 10:44 AM
	Fuller & Thaler Asset Management Inc. Acquires 8,600 Shares of Chemed Co. (CHE) www.americanbankingnews.com - March 1 at 10:50 AM
	Sei Investments Co. Buys 9,473 Shares of Chemed Co. (CHE) www.americanbankingnews.com - March 1 at 9:22 AM
	Chemed Co. (CHE) Shares Bought by BlackRock Inc. www.americanbankingnews.com - March 1 at 5:08 AM
	Teacher Retirement System of Texas Sells 247 Shares of Chemed Co. (CHE) www.americanbankingnews.com - February 28 at 5:07 PM
	Chemed Co. (CHE) Shares Bought by Rhumbline Advisers www.americanbankingnews.com - February 28 at 7:52 AM
	Chemed Co. (CHE) Holdings Lowered by Systematic Financial Management LP www.americanbankingnews.com - February 27 at 11:28 AM
	Chemed Corp (CHE) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - February 26 at 4:57 PM
	Chemed Co. (CHE) Shares Sold by Martingale Asset Management L P www.americanbankingnews.com - February 26 at 2:41 PM
	Eaton Vance Management Invests $19.97 Million in Chemed Co. (CHE) www.americanbankingnews.com - February 26 at 2:38 PM
	Chemed Co. (CHE) Shares Sold by Smith Asset Management Group LP www.americanbankingnews.com - February 25 at 2:28 PM
	California Public Employees Retirement System Sells 307 Shares of Chemed Co. (CHE) www.americanbankingnews.com - February 24 at 5:12 AM
	Chemed Co. (CHE) VP Naomi C. Dallob Sells 1,050 Shares www.americanbankingnews.com - February 21 at 12:31 PM
	Chemed Co. (CHE) to Issue $0.28 Quarterly Dividend www.americanbankingnews.com - February 16 at 2:36 PM
	Chemed (CHE) Receives "Hold" Rating from Royal Bank of Canada www.americanbankingnews.com - February 16 at 11:24 AM
	Oppenheimer Increases Chemed (CHE) Price Target to $275.00 www.americanbankingnews.com - February 16 at 11:24 AM
	Chemed Corporation to Present at the 2018 RBC Capital Markets’ Global Healthcare Conference finance.yahoo.com - February 15 at 5:06 PM
	Chemed Reports Fourth-Quarter 2017 Results finance.yahoo.com - February 15 at 6:58 AM

Chemed (NYSE:CHE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Chemed (NYSE:CHE) Income Statement, Balance Sheet and Cash Flow Statement

Chemed (NYSE CHE) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff